نتایج جستجو برای: rosuvastatin

تعداد نتایج: 1991  

2018
Pei Yu Ting Xiong Christine B. Tenedero Paul Lebeau Ran Ni Melissa E. MacDonald Peter L. Gross Richard C. Austin Bernardo L. Trigatti

OBJECTIVE Rosuvastatin has been widely used in the primary and secondary prevention of coronary heart disease. However, its antiatherosclerotic properties have not been tested in a mouse model that could mimic human coronary heart disease. The present study was designed to test the effects of rosuvastatin on coronary artery atherosclerosis and myocardial fibrosis in SR-B1 (scavenger receptor cl...

Journal: :Journal of the American College of Cardiology 2003
Dinko Susic Jasmina Varagic Jwari Ahn Michael Slama Edward D Frohlich

OBJECTIVES The goal of this research was to study the effects of rosuvastatin on systemic and regional hemodynamics in two hypertensive rat models, one genetic, the other induced with inhibition of nitric oxide synthesis. BACKGROUND Rats naturally have low cholesterol levels that are generally unaffected by statin therapy, thus providing a good model for studying cardiovascular effects unrela...

Journal: :Circulation journal : official journal of the Japanese Circulation Society 2012
Ryuji Nohara Hiroyuki Daida Mitsumasa Hata Kohei Kaku Ryuzo Kawamori Junji Kishimoto Masahiko Kurabayashi Izuru Masuda Ichiro Sakuma Tsutomu Yamazaki Hiroyoshi Yokoi Masayuki Yoshida

BACKGROUND A recent trial in Western countries has shown that rosuvastatin slows progression of carotid intima-media thickness (IMT) in patients with modest carotid IMT thickening and elevated levels of low-density lipoprotein cholesterol (LDL-C). We conducted a prospective, randomized, open-label, blinded-endpoint trial to determine whether rosuvastatin is more effective than pravastatin in sl...

Journal: :Journal of the American College of Cardiology 2002
Steven P Jones Michael F Gibson David M Rimmer Terrie M Gibson Brent R Sharp David J Lefer

OBJECTIVE We examined the possible effects of a novel 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, on endothelial nitric oxide (NO) production and myocardial ischemia-reperfusion injury. BACKGROUND Recent studies suggest that HMG-CoA reductase inhibitors promote vascular endothelial function through enhanced endothelial NO production. However, it is uncle...

2010
Paula K. Lorgelly Andrew H. Briggs Hans Wedel Peter Dunselman Åke Hjalmarson John Kjekshus Finn Waagstein John Wikstrand András Jánosi Dirk J. van Veldhuisen Vivencio Barrios Cândida Fonseca John J.V. McMurray

AIMS To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial. METHODS AND RESULTS This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and st...

2015
Ji-Yong Jang Sang-Hak Lee Byung Soo Kim Hong Seog Seo Woo-Shik Kim Youngkeun Ahn Nae-Hee Lee Kwang Kon Koh Tae-Soo Kang Sang-Ho Jo Bum-Kee Hong Jang-Ho Bae Hyoung-Mo Yang Kwang Soo Cha Bum Soo Kim Choong Hwan Kwak Deok-Kyu Cho Ung Kim Joo-Hee Zo Duk-Hyun Kang Wook Bum Pyun Kook Jin Chun June Namgung Tae-Joon Cha Jae-Hyeon Juhn YeiLi Jung Yangsoo Jang

BACKGROUND AND OBJECTIVES We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. SUBJECTS AND METHODS Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvast...

Journal: :Molecular pharmacology 2008
Anja Verhulst Rachel Sayer Marc E De Broe Patrick C D'Haese Colin D A Brown

Rosuvastatin is a potent HMG-CoA reductase inhibitor that has proven to be effective in the treatment of dyslipidemia. Rosuvastatin is cleared from the body by both biliary and renal clearance, the latter believed to be due to active tubular secretion. Whereas the mechanisms of hepatic clearance of rosuvastatin are well documented, those of renal clearance are not. Because rosuvastatin (and oth...

2013
JIANTING GAN PING LI ZHENGDONG WANG JIAN CHEN XIANGWEN LIANG MING LIU WENCHAO XIE RUIXING YIN FENG HUANG

An imbalance in the proliferation and migration of vascular smooth muscle cells (VSMCs) is significant in the onset and progression of vascular diseases, including arteriosclerosis and restenosis subsequent to vein grafting or coronary intervention. Rosuvastatin, a selective inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, has pharmacological properties including the ability t...

2017
Tae-Eun Kim Na Ha Yunjeong Kim Hyunsook Kim Jae Wook Lee Ji-Young Jeon Min-Gul Kim

Previous in vitro studies have demonstrated the inhibitory effect of green tea on drug transporters. Because rosuvastatin, a lipid-lowering drug widely used for the prevention of cardiovascular events, is a substrate for many drug transporters, there is a possibility that there is interaction between green tea and rosuvastatin. The aim of this study was to investigate the effect of green tea on...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2006
Liyue Huang Yi Wang Scott Grimm

MDR1/ABCB1, MRP2/ABCC2, and breast cancer resistance protein (BCRP)/ABCG2 are expressed in the liver and intestine and contribute to the disposition of many drugs. Rosuvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor for the treatment of patients with dyslipidemia, is primarily excreted via bile as unchanged drug. The present study was designed to determine whether rosuvastatin is...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید